Scribe Raises $129M in the First Gene-Editing IPO in Over Two Years

Gene-editing biotech Scribe Therapeutics has raised about $129 million in an initial public offering — the first IPO from a gene-editing company in more than two years.

Scribe priced 8.58 million shares at $15 and began trading on the Nasdaq as SCTX on July 23. The last gene-editing IPO was Metagenomi’s roughly $94 million offering in February 2024, making this a notable reopening for a sector that had gone quiet.

What epigenetic editing does differently

Rather than cutting DNA like classic CRISPR, Scribe uses an epigenetic approach that silences gene expression without altering the underlying sequence.

The mechanism uses the cell’s own regulatory machinery. Genes are switched off naturally by chemical marks — methyl groups on DNA, modifications on the histone proteins DNA wraps around — that make a region inaccessible to the transcription machinery.

An epigenetic editor pairs a disabled Cas protein, which finds a target sequence but cannot cut, with an enzyme that writes those silencing marks. It is guided to a gene’s control region and places the marks that switch it off.

The DNA sequence is unchanged. What changes is whether it is read.

Why that trade-off matters

Avoiding the cut removes the principal safety concern with conventional editing. A double-strand break relies on error-prone repair, can produce unintended insertions or deletions, and at off-target sites permanently alters the genome — with the theoretical possibility of disrupting a tumour suppressor.

The cost is durability. Epigenetic marks can be maintained through cell division, and whether silencing persists for years in humans is the central unproven question. If it fades, the treatment stops being one-time.

That reversibility is also an advantage in one respect: a silencing that could be undone is safer than a permanent edit if a problem emerges.

The lead programme

Lead programme STX-1150 targets PCSK9 to lower LDL cholesterol, with first-in-human data expected in the first half of 2027. Additional programmes aimed at Lp(a) and APOC3 are preclinical.

PCSK9 is the well-trodden choice, and deliberately so. The target is thoroughly validated: antibodies and RNA interference drugs against it are approved and lower LDL substantially, and people with natural loss-of-function variants have low cholesterol and no apparent harm.

That makes it a platform test rather than a biological gamble. If durable silencing works, the LDL reduction is predictable — so the readout measures the technology rather than the hypothesis.

Lp(a) is the more distinctive target. It is a genetically determined cardiovascular risk factor with no approved treatment and is largely unaffected by diet, statins or lifestyle — making it a genuine unmet need where a one-time intervention would be particularly valuable.

A cautious market

The raise was modest by 2026 standards — this year’s median biotech IPO has topped $300 million — reflecting Scribe’s earlier stage.

Still, it adds to a slowly reviving window: 14 biotechs went public through July, with several more lining up.

Why the sector went quiet

Gene editing raised enormous sums on the promise of one-time cures and then confronted commercial reality. The first approved CRISPR therapy treats a serious disease effectively and requires an intensive procedure at specialist centres at very high cost, and uptake has been slower than the science warranted.

That tempered enthusiasm for platforms whose value depends on delivering durable treatment affordably.

The delivery question behind every programme

Scribe’s choice of cardiometabolic targets is not only about validated biology — it reflects where genetic medicines can currently be delivered.

PCSK9, Lp(a) and APOC3 are all produced principally by the liver, which is the one organ that systemically administered genetic medicines reach reliably. Lipid nanoparticles accumulate there naturally, and a receptor on liver cells takes up particles bearing a specific sugar.

That is why the approved and advanced genetic medicines cluster so heavily in liver-expressed targets. It is not that liver diseases are the most pressing; it is that the liver is where the payload arrives.

An epigenetic editor faces an additional delivery constraint. It must be present in the cell only long enough to write the marks, after which its persistence is a liability rather than an asset — so transient delivery is preferable, which suits lipid nanoparticles well.

Extending beyond the liver is the field’s general problem, and it applies here as it does to RNA therapeutics generally. A platform validated on liver targets has demonstrated its editing chemistry; whether it can reach anywhere else is a separate technology question that a PCSK9 readout will not answer.

Whether appetite holds will depend on early clinical data — Scribe’s PCSK9 readout in 2027 will be an important test. Business news, not investment advice.